Jennifer K. Litton

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Real-world pregnancy outcomes following temporary interruption of adjuvant endocrine therapy in early-stage hormone receptor–positive breast cancer.

  Journal of Clinical Oncology · 2026-05-28

• IvoLoC: A phase II trial of ivonescimab (IVO) in endocrine-refractory hormone receptor (HR)–positive or triple-negative (TN) metastatic invasive lobular carcinoma (mILC).

  Journal of Clinical Oncology · 2026-05-28

• DCE-MRI for assessment of pathologic complete response after completion of neoadjuvant therapy in triple-negative breast cancer patients.

  Journal of Clinical Oncology · 2026-05-27

• Distant recurrence–free survival in invasive lobular carcinoma (ILC) with isolated tumor cells: Does pN0(i+) behave like node-negative or node-positive disease?

  Journal of Clinical Oncology · 2026-05-27

• Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansion

  Proceedings of the National Academy of Sciences · 2026-04-10 · 1 citations

• Abstract 3884: Multiplex immunofluorescence based spatial analysis of HER2 positive breast cancer patients treated with bintrafusp alfa: A translational pathology study.

  Cancer Research · 2026-04-03

• Abstract PS2-10-30: Tumor-associated macrophage (TAMs) and cancer-associated fibroblasts (CAFs) profiles in invasive lobular carcinoma (ILC) vs no special type (NST)

  Clinical Cancer Research · 2026-02-17

• Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancer

  npj Breast Cancer · 2025-11-20 · 3 citations

• SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade

  Nature · 2025-10-22 · 82 citations

• Imaging- and Tumor Biomarker–Based Multivariable Model for Early Prediction of Pathologic Complete Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer

  JCO Precision Oncology · 2025-10-01 · 2 citations

• ASO Visual Abstract: Complication Rates Are Low After Invasive Procedures on the Lactating Breast in Patients Treated for Breast Cancer During Pregnancy

  Annals of Surgical Oncology · 2025-08-07

• Complication Rates are Low After Invasive Procedures on the Lactating Breast in Patients Treated for Breast Cancer During Pregnancy

  Annals of Surgical Oncology · 2025-07-17 · 2 citations

• FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models

  Journal of Clinical Investigation · 2025-05-29 · 4 citations

• Early on-treatment (on-Rx) tumor volume reduction (TVR) to predict response to the KEYNOTE-522 (KN-522) regimen in early stage triple negative breast cancer (TNBC).

  Journal of Clinical Oncology · 2025-05-28

• Implications of omitting sentinel lymph node biopsy on adjuvant decision making for patients with small breast cancers

  Cancer · 2025-05-28 · 4 citations

• The impact of breast radiotherapy on the tumor genome and immune ecosystem

  Cell Reports · 2025-05-01 · 5 citations

• Multicancer Early Detection Tests at a Crossroads: Commercial Availability Ahead of Definitive Evidence

  American Society of Clinical Oncology Educational Book · 2025-04-22 · 4 citations

• SUPPLEMENTARY TABLE ST1 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study

  2025-04-03

• Supplementary Figure SF3 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II StudyPreprint

  2025-04-03

• SUPPLEMENTARY TABLE ST3 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study

  2025-04-03